Vancomycin Trough Target for Pediatric Osteomyelitis
For pediatric osteomyelitis, target vancomycin trough concentrations of 15-20 mg/L, consistent with adult guidelines for serious invasive infections like osteomyelitis. 1
Evidence-Based Recommendation
The 2009 IDSA/ASHP/SIDP consensus guidelines explicitly recommend trough concentrations of 15-20 mg/L for osteomyelitis to improve penetration, optimize target serum concentrations, and improve clinical outcomes 1. While these guidelines specifically state they are for adult patients only, they represent the highest-quality guideline evidence available and are routinely extrapolated to pediatric practice.
Critical Caveats and Practical Considerations
The Nephrotoxicity Risk Trade-off
Recent pediatric data reveals a significant concern: children with MRSA osteomyelitis who achieve higher vancomycin troughs face substantially increased acute kidney injury (AKI) risk. A 2025 study found that:
- 28.2% of children developed AKI (by KDIGO criteria) when treated with vancomycin for MRSA osteomyelitis 2
- Maximum trough levels >21.7 mg/L predicted AKI development 2
- Children with AKI had longer hospitalizations (19.9 vs 11.1 days) and dramatically higher costs ($117K vs $51K) 2
Dosing to Achieve Target Troughs
Standard pediatric dosing of 40-60 mg/kg/day frequently fails to achieve therapeutic troughs:
- In one study, 85% of children receiving 60 mg/kg/day had subtherapeutic levels (69% below target) 3
- Younger patients often require doses >60 mg/kg/day to reach target range 4
- Recent pharmacokinetic modeling suggests 75-80 mg/kg/day may be optimal for SSTI and bone/joint infections 5
The MIC Problem
When MRSA isolates have MIC ≥2 μg/mL, only 10% of children achieve therapeutic vancomycin levels 2. In these cases, strongly consider alternative antibiotics rather than escalating vancomycin doses and increasing AKI risk.
Practical Algorithm
Initial dosing: Start 60-80 mg/kg/day divided every 6-8 hours (FDA label suggests 10 mg/kg every 6 hours) 6
Check trough before 4th dose at steady state 1
Target 15-20 mg/L for osteomyelitis, but consider accepting 10-15 mg/L if:
- Patient is clinically improving
- MIC ≤1 μg/mL
- Renal function declining
- Trough approaching 20 mg/L (to avoid AKI risk)
Monitor renal function closely: Check creatinine every 2-3 days, as GFR inversely correlates with trough levels 7
If MIC ≥2 μg/mL: Strongly consider switching to alternative agents (daptomycin, linezolid, ceftaroline) rather than pursuing higher vancomycin troughs 2
Minimize duration: Limit vancomycin to shortest effective duration and transition to oral therapy when feasible to reduce AKI risk 2
Key Monitoring Parameters
- Trough concentrations remain the standard monitoring approach (not peak levels) 1
- GFR is the strongest predictor of vancomycin trough levels in children 7
- Baseline trough ≥10 mg/L should always be maintained to prevent resistance development 1
The evidence suggests a pragmatic approach: aim for 15-20 mg/L troughs as per guidelines, but accept 10-15 mg/L if clinical response is adequate, given the substantial AKI risk at higher levels in pediatric patients. This balances efficacy against the real-world toxicity data showing 28% AKI rates in this population 2.